What is the appropriate workup to diagnose fever in a patient receiving chemotherapy?

Diagnostic Workup for Chemotherapy-Induced Fever

In a patient receiving chemotherapy who develops fever, immediately obtain at least 2 sets of blood cultures (from each lumen of any central venous catheter and peripheral vein), complete blood count with differential, comprehensive metabolic panel, chest radiograph if respiratory symptoms are present, and cultures from any other clinically suspected infection sites 1.

Definition of Fever and Neutropenia

Before initiating workup, confirm the patient meets diagnostic criteria:

• Fever: Single oral temperature ≥38.3°C (101°F) OR sustained temperature ≥38.0°C (100.4°F) for 1 hour 1
• Neutropenia: Absolute neutrophil count (ANC) ≤500 cells/mm³, or ≤1000 cells/mm³ with predicted decline to ≤500 cells/mm³ 1

Critical note: Avoid rectal temperatures and rectal examinations during neutropenia 1.

Mandatory Initial Laboratory Workup

All patients require the following within 2 hours of presentation 1:

Blood Work

• Complete blood count with differential and platelet count
• Serum creatinine and blood urea nitrogen
• Electrolytes (including magnesium and phosphorus)
• Hepatic transaminases and total bilirubin
• Inflammatory markers: C-reactive protein, LDH, ferritin
• Coagulation studies: PT/PTT, fibrinogen
• Uric acid

Microbiological Cultures

Blood cultures are the cornerstone of diagnosis 1:

• Minimum of 2 sets of blood cultures before antibiotics
• If central venous catheter present: one set from each lumen PLUS one set from peripheral vein
• If no central catheter: 2 sets from separate venipunctures
• Limit total blood volume to <1% of total blood volume (usually 70 mL/kg) in patients <40 kg

Additional cultures based on clinical suspicion 1:

• Urine culture (obtain in all patients; yields positive results in ~16% of cases) 2
• Respiratory specimens if pulmonary symptoms present
• Stool culture if diarrhea present
• Wound/skin lesion cultures if applicable
• Other body fluid cultures as clinically indicated (pus, bile, bronchoalveolar lavage)

Risk Stratification Assessment

Immediately classify the patient as high-risk or low-risk using the MASCC score 1:

High-Risk Criteria (MASCC score <21)

• Anticipated prolonged neutropenia (>7 days duration)
• Profound neutropenia (ANC <100 cells/mm³)
• Hypotension
• Pneumonia
• New-onset abdominal pain
• Neurologic changes
• Uncontrolled cancer
• Poor functional status/advanced age
• Acute leukemia or post-HSCT status

Low-Risk Criteria (MASCC score ≥21)

• Anticipated brief neutropenia (<7 days)
• Few or no comorbidities
• Clinically stable

Imaging Studies

Chest Radiograph

Obtain in all patients with respiratory signs or symptoms 1:

• Cough, dyspnea, tachypnea
• Hypoxia
• Chest pain

Important caveat: Infiltrates may be absent early in neutropenia despite pulmonary infection due to impaired inflammatory response 3. If clinical suspicion remains high with negative chest X-ray, proceed to chest CT 4.

Additional Imaging

Consider chest CT scan if 4:

• Persistent fever after 48-72 hours despite antibiotics
• Respiratory symptoms with negative chest X-ray
• Suspected fungal infection (particularly after >7 days of neutropenia)
• Rising inflammatory markers without identified source

Abdominal imaging if abdominal pain, tenderness, or suspected intra-abdominal infection 1.

Physical Examination Focus

Despite neutropenia blunting typical inflammatory signs, carefully examine 3:

• Periodontium and pharynx
• Lower esophagus (dysphagia, odynophagia)
• Lungs (auscultation)
• Perineum and anus (avoid digital rectal exam)
• Skin: all IV sites, bone marrow aspiration sites, nail beds
• Eyes (fundoscopic exam for fungal lesions)
• Any site of pain

Timeline-Based Diagnostic Considerations

Early Fever (Days 1-3 of neutropenia)

• Bacterial infections predominate 5
• Blood culture positivity: ~13-17% 6, 2
• Most common organisms: Gram-negative bacilli (especially E. coli), Gram-positive cocci 7

Persistent Fever (Days 4-7)

If fever continues despite antibiotics, expand workup 8:

• Repeat blood cultures
• Chest CT scan (even if chest X-ray negative)
• Consider fungal biomarkers:
  • Serum galactomannan (threshold ≥0.5 in blood) 4
  • Beta-D-glucan
• Consider bronchoscopy with bronchoalveolar lavage if pulmonary infiltrates present

Prolonged Fever (>7 days)

Fungal infections become increasingly likely 4, 9:

• Aspergillus species most common mold
• Candida species (though candidemia typically occurs earlier)
• Consider empiric antifungal therapy even without documented infection

Special Populations

HIV-Positive Patients

Higher index of suspicion for opportunistic infections 10:

• Pneumocystis jirovecii pneumonia (PJP)
• Cytomegalovirus (CMV)
• Mycobacterium avium complex
• Consult infectious disease specialist early

Patients on Antifungal Prophylaxis

If breakthrough fever occurs 4:

• Switch antifungal class (e.g., if on azole, switch to liposomal amphotericin B)
• Consider resistant organisms
• Pursue aggressive diagnostic workup including bronchoscopy

What NOT to Consider as Causative

The following findings do not represent pathogens causing infection 4:

• Enterococci from blood culture, swabs, sputum, or BAL
• Coagulase-negative staphylococci (unless from blood culture with clinical correlation)
• Corynebacterium species
• Candida from sputum, saliva, or tracheal aspirates (not diagnostic of invasive candidiasis)
• Surveillance cultures from feces or urine (without clinical correlation)

Expected Diagnostic Yield

Realistic expectations based on evidence 2:

• Microbiologically documented infection: ~39% of cases
• Clinically suspected infection (no positive cultures): ~31% of cases
• Unknown cause of fever: ~30% of cases
• Blood culture positivity: 13-25% 6, 2

This means the majority of febrile neutropenia cases will NOT have a documented pathogen, but empiric treatment must still be initiated urgently 1.